Private company

GlobeStar Therapeutics Corp

GlobeStar Therapeutics Corp is an exclusive worldwide licensee for Project Amethyst™.¹ It is headquartered in Richland, Washington.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersRichland, Washington¹
Incorporated inWY²
Business address719 Jadwin Avenue, Richland, Wa 99352²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

GSTC is the exclusive worldwide licensee for Project Amethyst™, including all patents and patent applications relating thereto.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-48837.7%Gross margin⁴

-394377.9%Operating margin⁴

-703546.8%Net margin⁴

-81.9%Revenue growth, 2020⁴

-$241.5KFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2020

Cost of revenueInterest

Cost of revenue14¢$37.7K
Interest86¢$238.1K

Out of $77 in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁴$77 in 2020

Gross profit⁵⁶⁷⁴-$37.6K in 2020

Operating income⁵⁶⁷⁴-$303.7K in 2020−34% since 2017

Net income⁵⁶⁷⁴-$541.7K in 2020−68% since 2017

Fiscal year	2017	2018	2019	2020
Revenue	$0⁵	$890⁶	$425⁷	$77⁴
Cost of revenue	$0⁵	$207⁶	$154⁷	$37.7K⁴
Gross profit	$0⁵	$683⁶	$271⁷	-$37.6K⁴
Research and development
Operating expenses
Operating income	-$460.9K⁵	-$351.1K⁶	-$315.9K⁷	-$303.7K⁴
Interest	$635.7K⁵	$103.5K⁶	$360.4K⁷	$238.1K⁴
Income tax		$0⁵	$0⁶
Net income	-$1.7M⁵	-$816.7K⁶	-$675.1K⁷	-$541.7K⁴

Total assets⁵⁶⁷⁴$89.9K in 2020+266% since 2017

Total liabilities⁵⁶⁷⁴$749.1K in 2020+16% since 2017

Shareholders’ equity⁶⁷⁴¹⁰-$659.2K in 2020+6% since 2017

Cash⁶⁷⁴¹⁰$81.4K in 2020+478% since 2017

Fiscal year	2017	2018	2019	2020
Cash	$14.1K⁶	$91.6K⁷	$100.5K⁴	$81.4K¹⁰
Current assets	$14.8K⁵	$111.8K⁶	$141.4K⁷	$88.6K⁴
Total assets	$24.6K⁵	$124.7K⁶	$142.2K⁷	$89.9K⁴
Accounts payable
Current liabilities	$573.6K⁵	$995.5K⁶	$827.6K⁷	$749.1K⁴
Total liabilities	$648.5K⁵	$995.5K⁶	$827.6K⁷	$749.1K⁴
Retained earnings
Shareholders’ equity	-$624.0K⁶	-$870.7K⁷	-$685.4K⁴	-$659.2K¹⁰
Shares outstanding	45.6M shares⁵	85.1M shares⁵	210.3M shares⁶	445.5M shares⁷

Cash from operations⁵⁶⁷⁴-$239.7K in 2020+346% since 2017

Capital spending⁵⁶⁴$1.8K in 2020

Free cash flow⁵⁶⁷⁴-$241.5K in 2020+349% since 2017

Fiscal year	2017	2018	2019	2020
Cash from operations	-$53.7K⁵	-$180.1K⁶	-$260.1K⁷	-$239.7K⁴
Stock-based compensation
Capital spending	$0⁵	$1.4K⁶	$0⁶	$1.8K⁴
Free cash flow	-$53.7K	-$181.5K	-$260.1K	-$241.5K
Cash from financing

Compare GlobeStar Therapeutics Corp with another company

Leadership

Who has led GlobeStar Therapeutics Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

201520202025

Chief executive officerJames C. Katzaroff Apr 3, 2023 to Apr 4, 2023¹¹
Chief executive officerAlex K. Blankenship Jun 27, 2016 to Aug 25, 2020¹²
Chief executive officerRobert Federowicz Feb 4, 2014 to Feb 4, 2014¹³
ChairRobert Federowicz Feb 4, 2014 to Feb 4, 2014¹³
PresidentAlex K. Blankenship Aug 25, 2020 to Aug 25, 2020¹⁴
Chief financial officerRobert Chicoski May 3, 2023 to May 3, 2023¹⁵

Board members and other officers (6)

Executive officerJames C. Katzaroff Oct 13, 2020 to Oct 13, 2020¹⁶
Board memberJames C. Katzaroff Apr 3, 2023 to Apr 4, 2023¹¹
Board memberWilliam J. Farley Apr 23, 2021 to Apr 23, 2021¹⁷
Board memberBruce C. Badeau Jun 28, 2017 to Jun 28, 2017¹⁸
Board memberRobert W. Fryer Jun 30, 2017 to Jun 30, 2017¹⁹
Board memberAlex K. Blankenship Jun 27, 2016 to Aug 25, 2020¹²

Former names

AngioSoma, Inc.Jun 22, 2016 to May 21, 2021²
First Titan Corp.Nov 3, 2010 to Jun 16, 2016²

Timeline

Oct 28, 20248-K Executive or director change²⁰
Nov 13, 20238-K Other events²¹
Jun 27, 20238-K Change of auditor²²
Jun 22, 20238-K Other events²³
Apr 6, 20238-K Other events²⁴
Apr 3, 2023New chief executive James C. Katzaroff becomes CEO¹¹
Apr 11, 20228-K Unregistered sale of shares; Regulation FD disclosure²⁵
Oct 12, 20218-K Regulation FD disclosure²⁶
Oct 4, 20218-K Regulation FD disclosure; Other events²⁷
Jun 27, 2016New chief executive Alex K. Blankenship becomes CEO¹²
Feb 4, 2014New chief executive Robert Federowicz becomes CEO¹³

Filings

36 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 8 major events, 4 insider forms, 11 other. The latest 20:

The 36 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How GlobeStar Therapeutics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARGlobeStar Therapeutics Corp¹
CIK0001502152
Employer ID (EIN)27-3480481¹
Filer status<br>emerging growth company¹
Incorporated inWyoming¹
Fiscal year endsSeptember 30¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address719 Jadwin Avenue, Richland, WA 99352¹
Phone509-531-1671¹
Shares outstanding1,241,105,695 as of Oct 4, 2024⁹
Public float$4.9M as of Mar 31, 2023²⁸
On EDGAR sinceNov 3, 2010¹
Filings213 in all: 8-K (46), 10-Q (42), NT 10-Q (22), 10-Q/A (16), 10-K (13), NT 10-K (11), 3 (9), 10-K/A (8)¹
All 27 form types
UPLOAD (7), 4 (5), SC 13D (4), CORRESP (3), PRER14A (3), S-1/A (3), SC 13D/A (3), 4/A (2), 8-K/A (2), DEF 14A (2), PRE 14A (2), S-8 (2), SC 13G (2), 15-12G (1), 5 (1), 8-A12G (1), EFFECT (1), S-1 (1), SC 14F1 (1)
Latest filingsAnnual report (10-K) Jan 19, 2024
Quarterly report (10-Q) Oct 11, 2024
Proxy statement (DEF 14A) Sep 24, 2019
Latest 8-K (8-K) Oct 28, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARGlobeStar Therapeutics Corp filings on SEC EDGAR
2
SEC EDGARGlobeStar Therapeutics Corp filings on SEC EDGAR
3
SEC EDGARGlobeStar Therapeutics Corp annual report, Item 1 (Business)
4
SEC EDGARGlobeStar Therapeutics Corp 10-K for fiscal 2020
5
SEC EDGARGlobeStar Therapeutics Corp 10-K for fiscal 2017
6
SEC EDGARGlobeStar Therapeutics Corp 10-K for fiscal 2018
7
SEC EDGARGlobeStar Therapeutics Corp 10-K for fiscal 2019
8
SEC EDGARGlobeStar Therapeutics Corp 10-Q for fiscal 2024
9
SEC EDGARGlobeStar Therapeutics Corp 10-Q for fiscal 2024
10
SEC EDGARGlobeStar Therapeutics Corp 10-K for fiscal 2020
11
SEC EDGARJames C. Katzaroff, Chief executive officer
12
SEC EDGARAlex K. Blankenship, Chief executive officer
13
SEC EDGARRobert Federowicz, Chief executive officer
14
SEC EDGARAlex K. Blankenship, President
15
SEC EDGARRobert Chicoski, Chief financial officer
16
SEC EDGARJames C. Katzaroff, Executive officer
17
SEC EDGARWilliam J. Farley, Board member
18
SEC EDGARBruce C. Badeau, Board member
19
SEC EDGARRobert W. Fryer, Board member
20
SEC EDGARExecutive or director change
21
SEC EDGAROther events
22
SEC EDGARChange of auditor
23
SEC EDGAROther events
24
SEC EDGAROther events
25
SEC EDGARUnregistered sale of shares; Regulation FD disclosure
26
SEC EDGARRegulation FD disclosure
27
SEC EDGARRegulation FD disclosure; Other events
28
SEC EDGARGlobeStar Therapeutics Corp 10-K filed Jan 19, 2024: public float